SGIOF Projected Dividend Yield
Ord/Shionogi & Co., Ltd. ( OTCBB : SGIOF )Shionogi is the parent company of a group engaged in the research and development, purchase, manufacture and sale of pharmaceuticals, diagnostic reagents and medical devices. Co.'s principal prescription drugs are "Tivicay" for HIV treatment, "Mulpleta" for thrombocytopenia treatment, " Sympronic" for opioid-induced constipation treatment, " "Xofluza," influenza drug, and "Fetroja (cefiderocol)" for multidrug-resistant Gram-negative bacterial infection treatment. Co. is also engaged in the OTC drug business. Its principal products include "Sedes First," "Sedes Hi G," "Pylon," "Rapiacta Bag" and "Rapiacta Vial." 18 YEAR PERFORMANCE RESULTS |
SGIOF Dividend History Detail SGIOF Dividend News SGIOF Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend Amount (JPY) |
2024 |
N/A |
N/A |
Mar 29, 2024 |
Jun 21, 2024 |
28.3333 |
2024 Total: |
28.3333 |
||||
2023 |
N/A |
N/A |
Sep 30, 2023 |
Dec 01, 2023 |
25.0000 |
2023 |
N/A |
N/A |
Mar 31, 2023 |
Jun 22, 2023 |
25.0000 |
2023 Total: |
50.0000 |
||||
2022 |
N/A |
N/A |
Sep 30, 2022 |
Dec 01, 2022 |
20.0000 |
2022 |
N/A |
N/A |
Mar 31, 2022 |
Jun 24, 2022 |
20.0000 |
2022 Total: |
40.0000 |
||||
2021 |
N/A |
N/A |
Sep 30, 2021 |
Dec 01, 2021 |
18.3333 |
2021 |
N/A |
N/A |
Mar 31, 2021 |
Jun 23, 2021 |
18.3333 |
2021 Total: |
36.6666 |
||||
2020 |
N/A |
N/A |
Sep 30, 2020 |
Dec 01, 2020 |
17.6667 |
2020 |
N/A |
N/A |
Mar 31, 2020 |
Jun 24, 2020 |
17.6667 |
2020 Total: |
35.3334 |
||||
2019 |
N/A |
N/A |
Sep 30, 2019 |
Dec 02, 2019 |
16.6667 |
2019 |
N/A |
N/A |
Mar 31, 2019 |
Jun 19, 2019 |
16.6667 |
2019 Total: |
33.3334 |